MLYS
NASDAQMineralys Therapeutics Inc.
Mineralys Therapeutics Inc. (MLYS) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 16 wire items for MLYS, including 5 press releases and news items, 4 SEC filings and 4 insider trades. The most recent was published Nov 8, 2026.
MLYS rankings
Financial highlights
Full financials- Net income, TTM
- -$369.97M
- Cash
- $101.27M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks88+14%
2026-05-172026-11-08
Mix4090d
- SEC Filings14(35%)
- Other13(33%)
- Insider9(23%)
- Earnings2(5%)
- Analyst1(3%)
- Leadership1(3%)
Activity · 52 weeks174107 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRMineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026– In the largest long-term hypertension trial of an aldosterone synthase inhibitor to date, lorundrostat demonstrated sustained reduction in automated office systolic blood pressure (AOSBP) of 17.8 mmHg at Week 48 from Launch-HTN baseline – – 56% of participants reached AOSBP below 130 mmHg at Week 48 – – Long-term treatment with lorundrostat was well tolerated, with no new clinically relevant safety findings beyond Launch-HTN – – U.S. FDA review of lorundrostat is underway, with a PDUFA target date of December 22, 2026 – RADNOR, Pa., Nov. 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hyper
- PRMineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)RADNOR, Pa., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on November 3, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award covering 14,880 shares and an inducement restricted stock unit award covering 11,160 shares of Mineralys common stock to a new non-executive employee. The awards were granted under Mineralys’ 2025 Employm
- SECSEC Form 10-Q filed by Mineralys Therapeutics Inc.10-Q - Mineralys Therapeutics, Inc. (0001933414) (Filer)
- SECMineralys Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)
- PRMineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update– Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 – – New analyses from the pivotal Launch-HTN trial showed 46% of participants with uncontrolled or resistant hypertension receiving lorundrostat 50 mg achieved the AHA/ACC guideline systolic blood pressure target of <130 mmHg at Week 12 – – Transform-HTN open-label extension trial data selected for late-breaking presentation at American Heart Association Scientific Sessions 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hyp
- PRMineralys Therapeutics to Participate in Upcoming Investor ConferencesRADNOR, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that members of senior management will be participating in fireside chats at three upcoming investor conferences. Guggenheim Healthcare Innovation ConferenceDate:Tuesday, November 10, 2026Time:2:30pm ETFormat:Fireside ChatWebcast Link Stifel Healthcare ConferenceDate:Thursday, November 12, 2026Time:8:40am ETFormat:Fireside ChatW
- SECSEC Form 8-K filed by Mineralys Therapeutics Inc.8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)
- PRMineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026RADNOR, Pa., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced it will report its financial results from the third quarter ended September 30, 2026, after the financial markets close on Wednesday, November 4, 2026. Wednesday, November 4th @ 4:30 p.m. ETDomestic:1-877-704-4453International:1-201-389-0920Conference ID:13762560Webcast:Link A live webcast of the conference call may also be found on th
- PRMineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International- Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily added to an SGLT2 inhibitor achieved a statistically significant reduction in systolic blood pressure at four weeks - - New hormonal and urinary protein data show a 41.5% reduction in serum aldosterone with additional significant reductions in albuminuria and proteinuria - RADNOR, Pa., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea and other diseases driven by dysregulated al
- PRMineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026In the large, pivotal Phase 3 Launch-HTN trial, lorundrostat achieved similar significant blood pressure reductions in participants with and without CKD, with consistent reductions across Stages 1-3 CKD In participants with CKD, lorundrostat also reduced albuminuria by 52% versus placebo, validating similar findings in a prior trial in participants with established CKD RADNOR, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today
- INSIDERSEC Form 4 filed by Mineralys Therapeutics Inc.4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- INSIDERSEC Form 3 filed by Mineralys Therapeutics Inc.3 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- INSIDERSEC Form 4 filed by Mineralys Therapeutics Inc.4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- INSIDERSEC Form 3 filed by Mineralys Therapeutics Inc.3 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 8-K filed by Mineralys Therapeutics Inc.8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)
- PRMineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel CoatsRADNOR, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that Kristine Peterson and Lonnel Coats have been appointed to the Company’s Board of Directors. "We are delighted to welcome Kris and Lonnel to our Board of Directors as we prepare for the potential approval and commercial launch of lorundrostat for the treatment of uncontrolled or resistant hypertension," stated Jon Congleton, C
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- ANALYSTUBS initiated coverage on Mineralys Therapeutics with a new price targetUBS initiated coverage of Mineralys Therapeutics with a rating of Neutral and set a new price target of $29.00
- PRMineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressure target of <130 mmHg at 12 weeks, with more than two-thirds achieving ≥10 mmHg systolic blood pressure reduction - - In the Explore-OSA trial in participants with obstructive sleep apnea, lorundrostat 50 mg taken once daily in the evening achieved clinically meaningful reductions in morning systolic blood pressure with no measurable change in apnea-hypopnea indices - RADNOR, Pa., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focuse
- INSIDERChief Executive Officer Congleton Jon sold $1,909,665 worth of shares (75,000 units at $25.46) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 528,621 units (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- PRMineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026RADNOR, Pa., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that new data from the Launch-HTN trial of lorundrostat will be presented at the American Society of Nephrology Kidney Week 2026, taking place October 21-25 in Denver, Colorado. Oral Presentation Details: Title:Blood Pressure and Albuminuria Reduction with Lorundrostat in Chronic Kidney Disease Stages 1 to 3 in the Launch-HTN tria
- PRMineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026RADNOR, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that five abstracts will be presented at the American Heart Association (AHA) Hypertension Scientific Sessions 2026, taking place October 7-11 in Arlington, VA. Oral Presentation Details: Title:Efficacy and Safety of the Selective Aldosterone Synthase Inhibitor Lorundrostat in Moderate-to-Severe Obstructive Sleep Apnea and H
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- PRMineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)RADNOR, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on September 28, 2026, the Compensation Committee of Mineralys’ Board of Directors granted inducement stock option awards covering an aggregate of 46,430 shares and inducement restricted stock unit awards covering an aggregate of 34,823 shares of Mineralys common stock to two new non-executive employees. The awards were gra
- INSIDERDirector Slingsby Brian Taylor sold $3,005,303 worth of shares (104,320 units at $28.81) (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
MLYS FAQ
9 questionsWhat is the latest news on MLYS?
In the last 30 days Quantisnow tracked 16 wire items for MLYS: 5 press releases and news items, 4 SEC filings, 4 insider trades and 2 earnings updates. The most recent was published on November 8, 2026.Is MLYS profitable?
No. Mineralys Therapeutics Inc. reported a net loss of $369.97M for the twelve months ended Sep 30, 2026.How much cash and debt does MLYS have?
Mineralys Therapeutics Inc. reported $101.27M in cash and cash equivalents and $100.0K of debt on its most recent balance sheet in SEC filings.Where does MLYS stock trade?
Mineralys Therapeutics Inc. (MLYS) is listed on NASDAQ.What sector and industry is MLYS in?
Mineralys Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Mineralys Therapeutics Inc. go public?
Mineralys Therapeutics Inc. (MLYS) completed its IPO in 2023.What are analysts saying about MLYS?
Mineralys Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Neutral with a $29.00 price target on 2026-10-12. Recent price targets range from $15.00 to $39.00.What companies are similar to MLYS?
Notable peers in the same industry include NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.). Compare MLYS side-by-side with any of them on Quantisnow.How can I track MLYS on Quantisnow?
Quantisnow aggregates Mineralys Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MLYS to receive live email and push alerts on every new disclosure.